Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Ovarian Cancer
What chemotherapy would you utilize for a metastatic dysgerminoma diagnosed in the second trimester of pregnancy?
Answer from: Medical Oncologist at Community Practice
Cisplatinum, Etoposide, Bleomycin
Sign in or Register to read more
10409
Related Questions
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
What are your top takeaways in Gyn Cancers from ESMO 2024?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
How would you manage a rising CA-125 in a young patient on maintenance bevacizumab and olaparib x1 year for IIIC HR-deficient serous ovary cancer whose only finding on PETCT is a 1.5cm pelvic lymph node?
Would you offer trastuzumab-deruxtecan for a metastatic ovarian cancer patient with good performance status whose tumor stains 1+ on IHC for HER2 and who has exhausted all treatment options?
How do you manage patients with germline BRCA mutations who have STIC lesions found at the time of risk-reducing BSO?
For a patient with IIIC1 (micromets), MSI-high, Grade 2 endometrial adenocarcinoma who has undergone full surgical staging, do you recommend adding immunotherapy to adjuvant chemotherapy + radiation?
What are your top takeaways from SGO 2025?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?